作者
Carmela Gurrieri, Francesco Piazza, Marianna Gnoato, Barbara Montini, Lucia Biasutto, Cristina Gattazzo, Enrico Brunetta, Anna Cabrelle, Francesco Cinetto, Raffaele Niero, Monica Facco, Spiridione Garbisa, Fiorella Calabrese, Gianpietro Semenzato, Carlo Agostini
发表日期
2010/3/1
期刊
Journal of Pharmacology and Experimental Therapeutics
卷号
332
期号
3
页码范围
785-794
出版商
American Society for Pharmacology and Experimental Therapeutics
简介
Glycogen synthase kinase (GSK)-3 modulates the production of inflammatory cytokines. Because bleomycin (BLM) causes lung injury, which is characterized by an inflammatory response followed by a fibrotic degeneration, we postulated that blocking GSK-3 activity with a specific inhibitor could affect the inflammatory and profibrotic cytokine network generated in the BLM-induced process of pulmonary inflammation and fibrosis. Thus, here we investigated the effects of the GSK-3 inhibitor 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763) on a BLM-induced lung fibrosis model in mice. SB216763 prevented lung inflammation and the subsequent fibrosis when coadministered with BLM. Bronchoalveolar lavage fluid analysis of mice treated with BLM plus SB216763 revealed a significant reduction in BLM-induced alveolitis. Furthermore, SB216763 treatment was associated with a …
引用总数
20112012201320142015201620172018201920202021202220232024441072221326321